davidulmert

Director, Preclinical Theranostics Program at UCLA. Parka monkey. Tweets are my own.

[UCLA Jonsson Comprehensive Cancer Center @UCLAHealthJCCC]

We're proud to share Dr. Matthew Rettig received a VA Clinical Cancer Research Center grant to build a precision oncology hub for veterans in the Southwest, expanding access to clinical trials & advanced care for those who have sacrificed so much. https://t.co/lIpQgqmItL

[davidulmert @davidulmert]

Much appreciate Oliver Sartor’s editorial comment on our LRRC15-RIT. https://t.co/T6UoTKUe2e

[davidulmert @davidulmert]

@Dr_Singularity Thank you! Great post. Much appreciated.

[Dr Singularity @Dr_Singularity]

Big Cancer Breakthrough

UCLA Scientists Develop Antibody That Hunts and Destroys Aggressive Cancers

UCLA scientists have developed a powerful new cancer fighting antibody, DUNP19, that can both detect and destroy some of the deadliest, most treatment resistant tumors like osteosarcoma and glioblastoma.

This breakthrough "radiotheranostic" approach uses the same antibody for imaging and treatment - mild radiation to spot tumors, and stronger doses to wipe them out.

DUNP19 hunts down a protein called LRRC15, found on aggressive cancer cells but rarely in healthy tissue, allowing ultra precise targeting with minimal side effects.

In mice, this therapy stopped tumor growth, extended survival, and reprogrammed the tumor environment to make it vulnerable to immune attack, supercharging the effects of immunotherapy.

The first human clinical trial for patients with metastatic osteosarcoma is set to launch later this year. 👀

UCLA researchers say this could mark a major leap forward in fighting cancers once thought untreatable.

[UCLA Jonsson Comprehensive Cancer Center @UCLAHealthJCCC]

A team of researchers led by @davidulmert has identified a promising new treatment strategy that can detect, kill & reprogram aggressive, treatment-resistant tumors like osteosarcomas & glioblastoma.

https://t.co/HVb5RbCFvS

[Signal Transduction and Targeted Therapy (STTT) @sigtrans_sttt]

Demonstrating DUNP19, a monoclonal antibody targeting LRRC15, as a highly specific radio-theranostic modality for the non-invasive detection and mitigation of pro-tumorigenic mechanisms & immunotherapy resistance. @UCLA

#STTT #OpenAccess: https://t.co/QzubXpC76S

[Xia Yang Lab UCLA @YangLabUCLA]

Congratulations to Dr. David Ulmert @davidulmert and team for the promising new LRRC15-targeting radionuclide therapy for aggressive, treatment-resistant tumors! https://t.co/6fHU9qFMVb

[davidulmert @davidulmert]

https://t.co/1jd0TZAt7p

[LARVOL @Larvol]

Human kallikrein 2 (encoded by the KLK2 gene; KLK2) is a novel target expressed in prostate cancer cells. KLK2 pipeline — from radiopharmaceuticals to bispecifics and CAR-T —underscores an exciting era where KLK2-based modalities may transform prostate cancer diagnosis and treatment.

Abs: 5017 - Phase 1 study results of JNJ-78278343 (Pasritamig) in mCRPC (at @ASCO 2025) show Pasritamig as a first-in-class T-cell-redirecting BsAb binding KLK2.

Get the latest #ASCO25 updates as they happen: https://t.co/051z3BNE4z

#LARVOL #ProstateCancer #BsAb #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights | @TiansterZhang | @TapiaJC1 | @dralvaropinto | @PGrivasMDPhD | @DrRanaMcKay | @MattGalsky | @SuyogCancer

[Michael Serzan, MD @MikeSerzanMD]

🗣️Prostate Rapid Oral Abstract #ASCO25

👉Abst5017: Dr #CapucineBaldini
presenting #Pasritamig in mCRPC

🔑 KEY TAKE AWAYS
- #Pasritamig well tolerated (<10% G1 CRS @ RP2D) with promising antitumor activity.
- Proof of concept for #KLK2 as a target amenable to T-cell redirection.
- Unmet need for targeted #TcellTherapy safe to administer in an outpatient setting w/ meaningful benefit in mCRPC.

👥@neerajaiims @Silke_Gillessen @APCCC_Lugano @Prof_Nick_James @CParkMD @ChrisSweens1 @AtishChoudhury @TDorffOnc @xiaoweimd @CaPsurvivorship @drenriquegrande @bavilima @DRBakaloudiMD @nataliagandur @bergsa83 @OncoAlert @OncBrothers @urotoday @Uromigos

[Jordan Ciuro, MD @jordanciuro]

🔎Phase 1 results of JNJ-78278343 (pasritamig) in mCRPC? A first in class bispecific T-cell engager targeting human kallikrein2... a specific prostate antigen

✅Remarkable safety profile differentiated from prior T-cell engages with/ low rates of TRAE and infrequent CRS (8.9%, all grade 1 and did not require tocilizumab)
✅Achieved durable disease control and rPFS that compare to historical data in heavily pretreated mCRPC

@ASCO @oncoalert @Oncolive @TargetedOnc @OncoReporte @Urotoday #ASCO25 #genitourinarycancer @WinshipAtEmory

[Mark Wildgust (he/him) @MAWildgust]

Excited to share the first results from our ⁦@JNJInnovation⁩ new KLK2xCD3 investigational agent called pasritamig, a first-in-class, Bispecific T-Cell Engager Targeting Human Kallikrein 2 (KLK2) in #mCRPC. #MyCompany https://t.co/AUDmQyAz0H

[Mark Wildgust (he/him) @MAWildgust]

Oral presentation here @ASCO #ASCO25 describing a new target and mechanism in Prostate Cancer. #MyCompany

[Toni Choueiri, MD @DrChoueiri]

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from @GustaveRoussy et al. Full abstract → [https://t.co/yJgcuHCCxP]
@ASCO @ASCOPost @JCO_ASCO
@neerajaiims @montypal @bergsa83
@GlopesMd @VivekSubbiah @OncoAlert
@tompowles1 @OncBrothers @medicalwatchBC @yekeduz_emre
@CParkMD @Silke_Gillessen @PGrivasMDPhD
@TwoOncDocs @OncBrothers @Larvol @nataliagandur @crisbergerot @DrDanielHeng
@TiansterZhang @HammersMD @sonpavde @drenriquegrande @scserendipity1
@BraunMDPhD @Uromigos @AminNassarMD
@ZiadBakouny @DrRanaMcKay @NazliDizman

[UroToday.com @urotoday]

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac)-labeled antibody targeting human kallikrein 2, for #mCRPC. Presentation by @morr316 @MSKCancerCenter. #ASCO24 written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/4OvFbTQjzy

[Visegrád 24 @visegrad24]

There have been calls by some Muslim leaders to boycott Jewish products in solidarity with Palestine!

We would like to help the Muslim world in their boycott, and as such, here is a list of things that need to be avoided...

[Magnus Ranstorp @MagnusRanstorp]

Den talande tystnaden är öronbedövande.

Den antisemitism som blottat sig i samhället är skrämmande. Fler behöver träda fram och ställa sig upp och visa sitt stöd för vår judiska minoritet som är under bred attack i Sverige och i omvärlden! Det är oacceptabelt!

#NeverAgain

[Syed A. Ahmad @SyedAAhmad5]

The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer ⁦@CD_AACR⁩ ⁦@SWOG⁩ ⁦@AndrewMWaters⁩ https://t.co/FFEuMY5oZz

[Sabine D. Brookman-May @brookmans76]

EBRT increased AR pathway activity + [89Zr]11B6 uptake in PC bearing mice + [89Zr]11B6 uptake correlated with #hK2 protein levels. Further evaluation provided, [89Zr]11B6-PET imaging could be a potential monitoring tool for EBRT (or other treatments targeting AR axis/hK2)

[Sabine D. Brookman-May @brookmans76]

[89Zr]11B6-#PET imaging as a potential tool to monitor treatment response in #ProstateCancer: @davidulmert et al. show that #hK2 expression is a proxy of #AndrogenReceptor activity, which can be detected by non-invasive [89Zr]11B6-PET imaging https://t.co/tWUyI18YIL